Functional studies on the anti-pathoangiogenic properties of CM101

• Published in: Angiogenesis (London) Vol. 2; no. 3; pp. 219 - 233
• Main Authors: Yan, H P, Carter, C E, Wang, E Z, Page, D L, Washington, K, Wamil, B D, Yakes, F M, Thurman, G B, Hellerqvist, C G
• Format: Journal Article
• Language: English
• Published: Germany Springer Nature B.V 1998
• ISSN: 0969-6970; 1573-7209
• DOI: 10.1023/A:1009258801899

Group B streptococcus (GBS) isolated from human neonates diagnosed with sepsis and respiratory distress produces a polysaccharide exotoxin (CM101) which has been previously described as GBS toxin. CM101 infused i.v. into tumor-bearing mice causes rapid tumor neovascularitis, infiltration of inflammatory cells, inhibition of tumor growth and tumor apoptosis. CM101 has successfully completed phase I studies in refractory cancer patients with very encouraging results. We have now demonstrated a mechanism of action for CM101. Using a normal mouse tumor model, we have examined tumor and normal tissues which were harvested at 0, 5, 15, 30 and 60min post-infusion of either CM101 or dextran. We present evidence that CM101 is rapidly (within the first 5min) bound to the tumor neovasculature. Complement is activated by the alternative pathway (C3) and leukocytes start to infiltrate the tumor within the first 5min. Through RT-PCR and immunohistochemical techniques, we demonstrate that proinflammatory cytokines, interleukin-6 and tumor necrosis factor (TNF)-alpha, are up-regulated in infiltrating leukocytes and TNF receptor 2 is up- regulated in the targeted tumor neovasculature. Combined, these events constitute possible explanations for the observed pathophysiology of tumor ablation.